Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q3 FY24 results · Oct–Dec 2023
Procter & Gamble Health reported revenue from operations of ₹309.97 crore (up 0.0% from Q3 FY23) and net profit of ₹72.07 crore (down 6.2% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a standalone basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 309.97 | 309.97 | +0.0% | 304.93 | +1.7% |
| Other income | 5.18 | 4.54 | +14.1% | 6.05 | −14.4% |
| Total income | 315.15 | 314.51 | +0.2% | 310.98 | +1.3% |
| Profit before tax | 99.72 | 104.94 | −5.0% | 88.05 | +13.3% |
| Net profit for the period | 72.07 | 76.80 | −6.2% | 65.57 | +9.9% |
| EPS, basic (₹) | 43.40 | 46.30 | −6.3% | 39.50 | +9.9% |
| Net margin (%) | 23.3 | 24.8 | 21.5 |
Standalone
- Filed with BSE
- 08 Feb 2024, 10:38 IST
- Board meeting
- 06 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE